ATHENS, GREECE,PRNewswire-FirstCall/ - Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL), a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and cancer, announces that the anti-amnesic and neuroprotective effects of ANAVEX 1-41 are detailed in a paper published in the current edition of Neuropsychopharmacology. Currently in the late pre-clinical stage, ANAVEX 1-41 is one of the company's lead compounds for Alzheimer's disease (AD). Neuropsychopharmacology is an international scientific journal and the official publication of the American College of Neuropsychopharmacology, which focuses on clinical and basic science contributions that advance our understanding of the brain and behaviour.
"The ANAVEX 1-41 results highlighted in this important paper clearly demonstrate the compound's efficacy, which can be attained at extremely.......read the whole article
For more information on dementia, click here
If you are interested in dementia activities, click here